Anumigilimab

Phase 2Monoclonal antibody

CSL Behring

Anumigilimab is one of 40 biologic programs targeting Sickle Cell Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sickle Cell DiseaseActive, not recruiting

Sickle Cell DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

272 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Exjade

Novartis

Phase 3

4 2

Brilinta

AstraZeneca

Phase 3

3 3

Campath

GGenzyme, a Sanofi Company

Phase 3

12 4

Cysteine Hydrochloride

Novartis

Phase 3

2 5

Ritalin

Novartis

Phase 3

2 6

Eliquis

Bristol-Myers Squibb

Phase 3

1 7

Oxbryta

GGlobal Blood Therapeutics

Phase 3

5 8

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

4 9

Effient

CCosette Pharmaceuticals, Inc.

Phase 3

3 10

Endari

EEmmaus Medical, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Sickle Cell Disease

NCT07224360

Clinical

Trials by Indication[1]

Sickle Cell Disease1 trial

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Recruiting· CSL Behring logo

CSL Behring·Phase 2·NCT07224360·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anumigilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anumigilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anumigilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: CSL Behring

Anumigilimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Sickle Cell Disease1 trial

References

Drug Info

Quick Facts

Related News